NLTX CEO Interview - Part 2
from BioBusiness.TV, the podcast! ver2 Hosted by BioBusiness.TV / Peter M. Strumph, CEO, Nile Therapeutics / Matthew L. Kaplan, Managing Director, Healthcare Group, Ladenburg Thalmann
You are Watching: Nile’s CD-NP Phase 3 Strategy, and Secondary Pipeline Products, and 8 Person Team Peter Strumph lines up the milestones to come for Nile’s lead compound CD-NP and gives us a closer look at his strategy for determining the right dosage in Phase 2, in order to adequately prepare his Phase 3. Peter and Matt then discuss CU-NP and 2NTX-99, other pipeline products, Nile’s 8 person team and leverage model, as well as future in-licensing. This interview was conducted at the NASDAQ Marketsite, on September 3rd, 2008, in New York City. Featuring: * Peter M. Strumph, CEO, Nile Therapeutics * Matthew L. Kaplan, Managing Director, Healthcare Group, Ladenburg Thalmann DISCLAIMER: BIOBUSINESS.TV IS AN INDEPENDENT MEDIA, AND A PLATFORM FOR THE EXCHANGE OF IDEAS AND OPINIONS. BIOBUSINESS.TV STRIVES TO ENHANCE THE QUALITY AND ACCESSIBILITY OF INDUSTRY DATA, AND TO DELIVER INFORMATION THAT INVESTORS AND EXECUTIVES CAN RELY UPON TO MAKE SOUND, INFORMED FINANCIAL AND MANAGERIAL DECISIONS. VIEWERS SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
Embed this episode
No transcript yet.